Comparative Pharmacokinetics and Allometric Scaling of Carboplatin in Different Avian Species. 2015

Gunther Antonissen, and Mathias Devreese, and Siegrid De Baere, and Tom Hellebuyck, and Isabel Van de Maele, and Lieze Rouffaer, and Hendrickus J J Stemkens, and Patrick De Backer, and An Martel, and Siska Croubels
Department of Pharmacology, Toxicology and Biochemistry, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium; Department of Pathology, Bacteriology and Avian Diseases, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.

The use of chemotherapeutics as a possible treatment strategy in avian oncology is steadily increasing over the last years. Despite this, literature reports regarding dosing strategies and pharmacokinetic behaviour of chemotherapeutics in avian species are lacking. The aim of the present study was to investigate the pharmacokinetics of carboplatin in a representative species of the order of Galliformes, Anseriformes, Columbiformes and Psittaciformes. Eight chickens, ducks and pigeons and twenty-eight parakeets were administered carboplatin intravenously (5 mg/kg body weight). A specific and sensitive liquid chromatography-tandem mass spectrometry method was developed and validated for quantification of the free carboplatin in plasma of the four birds species (limit of quantification: 20 ng/mL for chicken and duck, 50 ng/mL for pigeon and 100 ng/mL for parakeets). Non-compartmental pharmacokinetic analysis and allometric scaling demonstrated a significant correlation (R² = 0.9769) between body weight (BW) and elimination half-life (T1/2el). T1/2el ranged from 0.41 h in parakeets (BW: 61 ± 8 g) to 1.16 h chickens (BW: 1909 ± 619 g). T1/2el is a good parameter for dose optimization of carboplatin in other avian species, since also the previously reported T1/2el in cockatoos (average BW: 769 ± 68 g) of 1.00 h corresponds to the results obtained in the present study.

UI MeSH Term Description Entries
D008297 Male Males
D001835 Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms. Body Weights,Weight, Body,Weights, Body
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001717 Birds Warm-blooded VERTEBRATES possessing FEATHERS and belonging to the class Aves. Aves,Bird
D016190 Carboplatin An organoplatinum compound that possesses antineoplastic activity. cis-Diammine(cyclobutanedicarboxylato)platinum II,Blastocarb,CBDCA,Carboplat,Carbosin,Carbotec,Ercar,JM-8,NSC-241240,Nealorin,Neocarbo,Paraplatin,Paraplatine,Platinwas,Ribocarbo,JM 8,JM8,NSC 241240,NSC241240

Related Publications

Gunther Antonissen, and Mathias Devreese, and Siegrid De Baere, and Tom Hellebuyck, and Isabel Van de Maele, and Lieze Rouffaer, and Hendrickus J J Stemkens, and Patrick De Backer, and An Martel, and Siska Croubels
November 2011, Clinical pharmacokinetics,
Gunther Antonissen, and Mathias Devreese, and Siegrid De Baere, and Tom Hellebuyck, and Isabel Van de Maele, and Lieze Rouffaer, and Hendrickus J J Stemkens, and Patrick De Backer, and An Martel, and Siska Croubels
November 1998, Acta pharmaceutica Hungarica,
Gunther Antonissen, and Mathias Devreese, and Siegrid De Baere, and Tom Hellebuyck, and Isabel Van de Maele, and Lieze Rouffaer, and Hendrickus J J Stemkens, and Patrick De Backer, and An Martel, and Siska Croubels
May 2021, Biopharmaceutics & drug disposition,
Gunther Antonissen, and Mathias Devreese, and Siegrid De Baere, and Tom Hellebuyck, and Isabel Van de Maele, and Lieze Rouffaer, and Hendrickus J J Stemkens, and Patrick De Backer, and An Martel, and Siska Croubels
August 2023, ACS omega,
Gunther Antonissen, and Mathias Devreese, and Siegrid De Baere, and Tom Hellebuyck, and Isabel Van de Maele, and Lieze Rouffaer, and Hendrickus J J Stemkens, and Patrick De Backer, and An Martel, and Siska Croubels
January 2014, Polish journal of veterinary sciences,
Gunther Antonissen, and Mathias Devreese, and Siegrid De Baere, and Tom Hellebuyck, and Isabel Van de Maele, and Lieze Rouffaer, and Hendrickus J J Stemkens, and Patrick De Backer, and An Martel, and Siska Croubels
February 1984, The American journal of physiology,
Gunther Antonissen, and Mathias Devreese, and Siegrid De Baere, and Tom Hellebuyck, and Isabel Van de Maele, and Lieze Rouffaer, and Hendrickus J J Stemkens, and Patrick De Backer, and An Martel, and Siska Croubels
April 2003, Biopharmaceutics & drug disposition,
Gunther Antonissen, and Mathias Devreese, and Siegrid De Baere, and Tom Hellebuyck, and Isabel Van de Maele, and Lieze Rouffaer, and Hendrickus J J Stemkens, and Patrick De Backer, and An Martel, and Siska Croubels
February 1997, The Journal of pharmacy and pharmacology,
Gunther Antonissen, and Mathias Devreese, and Siegrid De Baere, and Tom Hellebuyck, and Isabel Van de Maele, and Lieze Rouffaer, and Hendrickus J J Stemkens, and Patrick De Backer, and An Martel, and Siska Croubels
April 2000, Pharmaceutical research,
Gunther Antonissen, and Mathias Devreese, and Siegrid De Baere, and Tom Hellebuyck, and Isabel Van de Maele, and Lieze Rouffaer, and Hendrickus J J Stemkens, and Patrick De Backer, and An Martel, and Siska Croubels
August 2011, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!